Clene reports positive Phase 2 VISIONARY-MS LTE results for CNM-Au8 at AAN; shows repair and remyelination evidence

Clene Inc.

CNM-Au8 treatment up to 3 years showed significant vision improvement (low contrast letter acuity, p<0.001) and cognition (SDMT, p<0.001) vs original baseline.
Physiologic markers of remyelination improved: mfVEP amplitude p<0.01, latency p=0.06.
MRI measures of T2 lesion myelin water fraction and magnetization transfer ratio improved (p<0.05 and p=0.06), indicating structural repair.
No significant safety findings; CNM-Au8 well-tolerated over long-term.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.